An interventional study of BiWaze Clear System in Bronchiectasis and Pulmonary Exacerbation, sponsored by Delve Health. Recruiting at 5 sites in United States. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Delve Health · Not applicable, Interventional, and Treatment
The study will examine how the performance of Oscillating Lung Expansion (OLE) therapy affects the respiratory health of patients with Bronchiectasis (BE).
The patient will use the BiWaze Clear system for their airway clearance therapy, instead of their previously prescribed therapy. BiWaze Clear is an FDA-cleared respiratory therapy for assisting patients in loosening and mobilizing secretions as well as treating and preventing atelectasis by providing lung expansion and high-frequency oscillation therapies, combined with aerosol delivery.
The patient will perform airway clearance with BiWaze Clear as prescribed. The system uses a disposable breathing circuit, which is a single patient use, disposable circuit.
The treatment duration is 6 months . The BiWaze Clear System is indicated for the mobilization of secretions, lung expansion therapy, the treatment and prevention of pulmonary atelectasis and has the ability to provide supplemental oxygen when used with an oxygen supply.
The BiWaze Clear System is indicated for the mobilization of secretions, lung expansion therapy, the treatment and prevention of pulmonary atelectasis and has the ability to provide supplemental oxygen when used with an oxygen supply.
The BiWaze Clear System is indicated to deliver therapy to adults and children over the age of 5 years in the home care setting. The primary objective of the study is to evaluate the effectiveness of BiWaze Clear therapy in reducing the frequency of pulmonary exacerbations and improving clinical outcomes.
The study will quantify the frequency of pulmonary exacerbations over a 6-month period during BiWaze Clear therapy and compare this data to the number of exacerbations recorded in the 12 months prior to the initiation of therapy.
A total of 85 adult and pediatric male and female patients (5+ years of age) that are diagnosed with Bronchiectasis(BE) will be enrolled into the study.
The patient will perform airway clearance therapy with the BiWaze Clear System. This system is manufactured by ABM Respiratory Care and assists patients in loosening and mobilizing secretions as well as treating and preventing atelectasis by providing lung expansion and high frequency oscillation therapies. The oscillating lung expansion therapy of the BiWaze Clear System is intended to reduce airway obstructions caused by secretions occupying the lower airways, prevent respiratory tract infections, re-expand the collapsed areas of the lung, thereby enhancing gas exchanges and reducing inflammatory response.
BiWaze Clear provides three respiratory therapies: Positive Expiratory Pressure (PEP), Oscillation (OSC), and Nebulize (NEB).
The study will start with screening patients to confirm eligibility before enrollment Day(-7 to-1). At the screening visit, Informed Consent will be discussed and obtained and signed prior to any study procedures. Potential subjects will be screened by inclusion and exclusion criteria, Medical History and respiratory history will be obtained and documented.
At Visit 1 (Day 1), baseline assessment will be performed, including vital signs, respiratory rate , oxygen saturation, measuring height and weight, recording medical and respiratory history, conduct urine pregnancy test for the female that is able to be pregnant. Bronchiectasis symptoms will be collected , Quality of Life-Bronchiectasis questionnaire will be completed, as well as measuring Forced Expiratory Volume( FEV1) and Forced Vital Capacity (FVC).
Biwaze Clear System Device will be dispensed to the patients. Patients will receive their device training. Remote data-captured devices will be dispensed and provided to the patients along with the respective training.
after the base line visit , there will be another 2 onsite visits where the patients should visit their study sites , Visit 2 ( Day 90) and Visit 3 ( day 180). During these 2 visits, patient's weight will be measured and recorded. V ital signs, respiratory rate, and oxygen saturation will be recorded. Quality of Life-Bronchiectasis questionnaire will be completed, as well as measuring Forced Expiratory Volume( FEV1) and Forced Vital Capacity (FVC). All related AEs and SAEs will be recorded , documented and reported as well as Bronchiectasis symptoms will be collected .
In addition of the screening, baseline visits and onsite visits 2 and 3 , a weekly remote data capture devices will record and report the remote monitoring assessments of study endpoints, including vital signs , respiratory rate, and oxygen saturation, Forced Expiratory Volume( FEV1) and Forced Vital Capacity (FVC) and Bronchiectasis symptoms will be recorded. In addition Quality of Life-Bronchiectasis questionnaire will be completed on a monthly basis.
404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.
This study's planned enrollment of 85 is above the median of 60 across 263 interventional studies indexed under Bronchiectasis.
Browse Bronchiectasis studies →This is the only study on the registry with Delve Health as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible to participate in this study, an individual must meet all of the following criteria:
Exclusion Criteria
An individual who meets any of the following criteria will be excluded from participating in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients will be assigned to a single treatment arm utilizing BiWaze Clear System
Device: BiWaze Clear System
The BiWaze Clear device includes several components as follows: 1. BiWaze Clear System. 2. BiWaze Clear Dual Lumen Breathing Circuit. * Dual Lumen bacterial/viral filter. * Dual Lumen breathing tube. * Patient Interface (Anesthesia mask \[small, medium or large\], Mouthpiece, or trach adapter). 3. Carrying Bag. The patient will perform airway clearance therapy with the BiWaze Clear System
Evaluate the effectiveness of BiWaze Clear therapy in reducing the frequency of pulmonary exacerbations and improving clinical outcomes.
Quantify the frequency of pulmonary exacerbations over a 6-month period during BiWaze Clear therapy and compare this data to the number of exacerbations recorded in the 12 months prior to the initiation of therapy.
Time frame: 6 months
Plan to share: Yes
Supporting information: Statistical analysis plan, Clinical study report
Time frame: Q3-2026
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for May 2026, 12 months after the start.
Of 72 non-industry interventional studies with no phase under Bronchiectasis, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 67. This study's planned 12 months is below that.
Counting every sponsor, half of 78 studies reached it within 20 months; a quarter within 10 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.